Peptide therapeutics are revolutionizing healthcare, but their complexity requires more than routine analysis. Success depends on strategic study design, expert data interpretation, and clear scientific communication. Our consulting services help you navigate these challenges with confidence, ensuring your peptide programs are scientifically robust and regulatory-ready.
We provide strategic consulting for both established generic peptide formulations and innovative novel delivery systems. By aligning formulation strategies with FDA, EMA, and ICH guidelines, we position your peptide products for smooth regulatory approval and commercial success.
We guide the design of studies to confirm peptide identity, sequence, and structural integrity. Our consulting ensures datasets are comprehensive, reproducible, and aligned with FDA, EMA, and ICH expectations.
We help structure impurity studies that capture charge variants, degradation pathways, and aggregation tendencies. Our expertise ensures impurity profiles meet ICH thresholds and strengthen your regulatory submissions.
For generics and biosimilars, demonstrating equivalence is essential. We provide strategic frameworks for comparability studies, ensuring structural, functional, and pharmacokinetic data are analyzed and communicated effectively.
We advise on study design using chromatographic and mass spectrometry approaches, ensuring accurate detection of modifications and degradation products.
We interpret NMR, CD, FTIR, and aggregation data to provide clarity on peptide conformation and stability.
Strategic consulting on stability programs for both Active Pharmaceutical Ingredient (API) and Drug Product (DP). We help identify degradation pathways, interpret stability data, and ensure compliance with global regulatory standards.